Look at the following information from the press release Lilly (NYSE: LLY) issued this morning when they announced earnings;
“For the first quarter of 2018, worldwide Humalog revenue increased 12 percent compared with the first quarter of 2017, to $791.7 million. Revenue in the U.S. increased 12 percent, to $504.1 million driven by higher realized prices due to changes in estimates to rebates and discounts and changes in payer segment mix, and, to a lesser extent, increased volume. Revenue outside the U.S. increased 11 percent, to $287.6 million, driven by the favorable impact . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.